Our Patients

Our Promise to Patients: You Come First

Welcome home

You've likely had a long journey, but now you're among friends. We understand serious and rare diseases because we've specialized in them for decades and we're here to help. By working closely with people like Emily and her family (pictured above), we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, and Alpha 1 antitrypsin deficiency.

We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. Watch this video from our Chief Medical Officer to hear more about our commitment to you. We offer support programs and activities and we partner with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

Read Our Letter to Patients

How can we help you?

Immunodeficiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Within the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)

Outside the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Secondary Immunodeficiency
- Kawasaki Disease (KD)
- Guillain-Barré Syndrome (GBS)

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Within the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency

Outside the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency
- Factor X Deficiency

Hereditary Angioedema (HAE)

We introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha 1 Antitrypsin Deficiency

Our Alpha 1 proteinase inhibitor treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with Alpha 1-related emphysema.

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area	Condition	Study Number	Description	Status ^{(Click on link to learn more)}
Haematology and Thrombosis	Hemophilia A	CSL627_3001	An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A	Active, Not Recruiting
	Hemophilia B	CSL654_3003	A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B	Active, Not Recruiting
	Hemophilia A & B	CSL689_2001	Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors	Cancelled
	Congenital Fibrinogen Deficiency	BI3023_4003	An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency	Completed
	Von Willebrand Disease	CSLCT-BIO-12-83	Study of Voncento^® in Subjects With Von Willebrand Disease	Completed
	Reversal of acquired coagulation factor deficiency	BE1116_4001	An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra^® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding	Recruiting
	Sickle Cell	CSL200_1001	CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Active, Not Recruiting
Cardiovascular and Metabolic	Acute Coronary Syndrome	CSL112_3001	Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)	Active, Not Recruiting
	Coronary Heart Disease	CSL112_1001	Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults	Completed
Immunology and Neurology	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro20_3004	Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Results
	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro10_5004	Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)	Completed
	Dermatomyositis (DM)	IgPro20_3007	A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM)	Active, Not Recruiting
	Pediatric CIDP	IgPro10_4002	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	Active, Not Recruiting
	Hereditary Angioedema (HAE)	CSL312_2001	A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)	Recruiting
	Hidradenitis Suppurativa and Palmoplantar Pustulosis	CSL324_1002	A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis	Active, Not Recruiting
	Primary Immune Deficiency (PID)	IgPro20_4004	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra^®) in Subjects With Primary Immunodeficiency (PID)	Completed
	Primary Immune Deficiency (PID)	IgPro20_4005	Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra^®) on Weekly and Biweekly Schedules	Results
	Primary Immune Deficiency (PID)	IgPro20_1001	Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump	Completed
	Systemic Sclerosis	IgPro10_2001	Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis	Active, Not Recruiting
	Systemic Sclerosis	IgPro20_2001	A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc)	Active, Not Recruiting
	Healthy Subjects	CSL730_1001	Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults	Active, Not Recruiting
	Healthy Subjects	CSL324_1001	Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults	Completed
Respiratory	Mild Asthma	CSL311_1001	A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma.	Active, Not Recruiting
Transplant	Antibody-mediated kidney transplant rejection	CSL842_3001	Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients	Active, Not Recruiting
	Acute GVHD (aGVHD)	CSL964_2001	The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)	Recruiting
	Graft Versus Host Disease (GVHD)	CSL964_5001	A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD	Active, Not Recruiting

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More